Abstract
From June to October 2019, 17 patients (six infected, 11 colonised) with an extensively drug-resistant (XDR) Klebsiella pneumoniae strain were notified from four Western Pomerania medical facilities. The XDR K. pneumoniae produced carbapenemases NDM-1 and OXA-48, and was only susceptible to chloramphenicol, tigecycline and cefiderocol. Synergistic activity was observed for the combination of aztreonam plus ceftazidime-avibactam. Genomic analyses showed all isolates belonged to K. pneumoniae sequence type 307. Control measures and further investigations are ongoing.
Keywords:
CTX-M; Enterobacterales; NDM-1; OXA-48; XDR; clonal spread; colistin resistance.
MeSH terms
-
Anti-Bacterial Agents / pharmacology*
-
Anti-Bacterial Agents / therapeutic use
-
Bacterial Proteins
-
Cross Infection / epidemiology*
-
Disease Outbreaks*
-
Drug Resistance, Multiple, Bacterial / genetics
-
Humans
-
Klebsiella Infections / diagnosis
-
Klebsiella Infections / drug therapy
-
Klebsiella Infections / epidemiology*
-
Klebsiella pneumoniae / drug effects
-
Klebsiella pneumoniae / genetics
-
Klebsiella pneumoniae / isolation & purification*
-
Microbial Sensitivity Tests
-
Sequence Analysis
-
beta-Lactamases*
Substances
-
Anti-Bacterial Agents
-
Bacterial Proteins
-
beta-Lactamases
-
beta-lactamase CTX-M-17, Klebsiella pneumoniae
-
beta-lactamase NDM-1
-
carbapenemase
-
oxacillinase